244 related articles for article (PubMed ID: 35748691)
1. Recent advances in therapeutic options for rare hemostatic disorders: selected poster extracts of recent research in hemophilia A, congenital hemophilia with inhibitors, von Willebrand disease, and thrombotic thrombocytopenic purpura presented at the 29th congress of the International Society on Thrombosis and Haemostasis (ISTH 2021, Jul 17-21; virtual congress).
Jain N; Oldenburg J; Ozelo MC; Sun SX; Tang L; Tzivelekis S
Expert Rev Hematol; 2022 May; 15(sup1):1-18. PubMed ID: 35748691
[TBL] [Abstract][Full Text] [Related]
2. European Renal Best Practice endorsement of guidelines for diagnosis and therapy of thrombotic thrombocytopaenic purpura published by the International Society on Thrombosis and Haemostasis.
Eller K; Knoebl P; Bakkaloglu SA; Menne JJ; Brinkkoetter PT; Grandt L; Thiem U; Coppo P; Scully M; Haller MC
Nephrol Dial Transplant; 2022 Jun; 37(7):1229-1234. PubMed ID: 35195251
[TBL] [Abstract][Full Text] [Related]
3. Addressing unmet needs in rare bleeding disorders: selected poster extracts of recent research in hemophilia A and von Willebrand disease presented at the 14th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) (Feb 3-5, 2021; virtual congress).
Allen G; Du P; Khair K; Lee HY; Ozelo MC; Berthoz FT; Windyga J
Expert Rev Hematol; 2021 Sep; 14(sup1):1-18. PubMed ID: 34369834
[TBL] [Abstract][Full Text] [Related]
4. Interactions of von Willebrand factor and ADAMTS13 in von Willebrand disease and thrombotic thrombocytopenic purpura.
Budde U; Schneppenheim R
Hamostaseologie; 2014; 34(3):215-25. PubMed ID: 25010251
[TBL] [Abstract][Full Text] [Related]
5. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.
Tsai HM; Lian EC
N Engl J Med; 1998 Nov; 339(22):1585-94. PubMed ID: 9828246
[TBL] [Abstract][Full Text] [Related]
6. Von Willebrand Disease, Hemophilia, and Other Inherited Bleeding Disorders in Pregnancy.
Pacheco LD; Saade GR; James AH
Obstet Gynecol; 2023 Mar; 141(3):493-504. PubMed ID: 36800851
[TBL] [Abstract][Full Text] [Related]
7. von Willebrand factor and animal models: contributions to gene therapy, thrombotic thrombocytopenic purpura, and coronary artery thrombosis.
Brinkhous KM; Reddick RL; Read MS; Nichols TC; Bellinger DA; Griggs TR
Mayo Clin Proc; 1991 Jul; 66(7):733-42. PubMed ID: 2072761
[TBL] [Abstract][Full Text] [Related]
8. Structural and functional correlation of ADAMTS13.
Dong JF
Curr Opin Hematol; 2007 May; 14(3):270-6. PubMed ID: 17414218
[TBL] [Abstract][Full Text] [Related]
9. [Thrombotic Thrombocytopenic Purpura --Pathophysiology and Assays of ADAMTS13 Activity].
Kato S; Fujimura Y
Rinsho Byori; 2015 Oct; 63(10):1228-36. PubMed ID: 26897861
[TBL] [Abstract][Full Text] [Related]
10. Link between von Willebrand factor multimers, relapses and coronary microcirculation in patients with thrombotic thrombocytopenic purpura in remission.
Di Pasquale I; Budde U; Tona F; Bertomoro A; Lombardi AM; Famoso G; Bertozzi I; Dittmer R; Schneppenheim S; Fabris F
Thromb Res; 2019 Jan; 173():42-47. PubMed ID: 30471507
[TBL] [Abstract][Full Text] [Related]
11. Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura.
Hollifield AL; Arnall JR; Moore DC
Am J Health Syst Pharm; 2020 Jul; 77(15):1201-1207. PubMed ID: 32588878
[TBL] [Abstract][Full Text] [Related]
12. von Willebrand factor and thrombotic thrombocytopenic purpura.
Raife TJ; Montgomery RR
Curr Opin Hematol; 2000 Sep; 7(5):278-83. PubMed ID: 10961577
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in thrombotic thrombocytopenic purpura.
Sadler JE; Moake JL; Miyata T; George JN
Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
[TBL] [Abstract][Full Text] [Related]
14. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
Furlan M; Robles R; Galbusera M; Remuzzi G; Kyrle PA; Brenner B; Krause M; Scharrer I; Aumann V; Mittler U; Solenthaler M; Lämmle B
N Engl J Med; 1998 Nov; 339(22):1578-84. PubMed ID: 9828245
[TBL] [Abstract][Full Text] [Related]
15. [Advance in the diagnosis and treatment of hereditary thrombotic thrombocytopenic purpura].
Liu W; Xiao Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2022 Apr; 39(4):442-446. PubMed ID: 35446985
[TBL] [Abstract][Full Text] [Related]
16. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.
Furlan M; Lämmle B
Best Pract Res Clin Haematol; 2001 Jun; 14(2):437-54. PubMed ID: 11686108
[TBL] [Abstract][Full Text] [Related]
17. An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura.
Joly BS; Coppo P; Veyradier A
Expert Rev Hematol; 2019 Jun; 12(6):383-395. PubMed ID: 31107120
[No Abstract] [Full Text] [Related]
18. [Von Willebrand factor and ADAMTS13 balancing primary haemostasis].
Schneppenheim R; Budde U
Hamostaseologie; 2011 Nov; 31(4):275-80. PubMed ID: 21792464
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for thrombotic thrombocytopenic purpura.
Cataland SR; Wu HM
Curr Opin Hematol; 2005 Sep; 12(5):359-63. PubMed ID: 16093780
[TBL] [Abstract][Full Text] [Related]
20. The Hemostatic Conundrum of Thrombotic Thrombocytopenic Purpura: a Case Report.
Pillay E; Louw S
Clin Lab; 2019 Jun; 65(6):. PubMed ID: 31232040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
